Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Response to "Comment on Cancer Treatment Modalities and Female Fertility Preservation".

Pharmacotherapy·2026

Same journal

Women's Health in Oncology.

Pharmacotherapy·2026

Same journal

Comment on "Cancer Treatment Modalities and Female Fertility Preservation".

Pharmacotherapy·2026

Same journal

Comparison of Bayesian and First-Order Estimations of Vancomycin Area Under the Curve in Pediatrics Using One- and Two-Concentration Methods.

Pharmacotherapy·2026

Same journal

A Data-Driven Medication Regimen Complexity Score for Critically Ill Patients: MRC-ICU 2.0.

Pharmacotherapy·2026

Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026

Search research articles

Related Experiment Video

Updated: May 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Meloxicam-induced thrombocytopenia.

Melissa M Ranieri¹, Elizabeth F Bradley, Allison B Simon

¹Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, Pennsylvania.

Pharmacotherapy

|November 12, 2013

Summary

A rare case of immune thrombocytopenia linked to meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), is presented. Prompt recognition of drug-induced thrombocytopenia is crucial for patient safety and effective treatment.

Keywords:

drug-induced immune thrombocytopenia meloxicam nonsteroidal antiinflammatory drugs thrombocytopenia

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Experiment Videos

Last Updated: May 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Area of Science:

Pharmacology
Hematology
Immunology

Background:

Immune thrombocytopenia (ITP) is a rare but serious condition.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause thrombocytopenia.
Meloxicam-associated ITP is exceptionally rare, with only one prior case reported.

Observation:

An 84-year-old woman developed severe thrombocytopenia after her first dose of meloxicam.
Her platelet count dropped drastically from 267 × 10(3)/mm(3) to 2 × 10(3)/mm(3).
Symptoms included bruising and black stools, coinciding with meloxicam administration.

Findings:

The rapid onset and severity suggest an idiosyncratic drug reaction.
Causality assessment using the Hill criteria supports meloxicam as the likely cause.
This case highlights a rare adverse drug event associated with meloxicam.

Implications:

Healthcare providers should consider meloxicam as a potential cause of ITP.
Thorough medication history is vital for diagnosing unusual symptoms.
Early identification and treatment of drug-induced ITP are critical to prevent life-threatening complications.